Norman James Lacayo, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lacayo’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence G71335 · Current
Licensed to practise in California · since 1991 · expires 2027-01-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$75,586 in 2024
Medicaid paid $75,586 for 945 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 318 | $66,178 |
| Service | 177 | $6,036 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 199 | $1,767 |
| Measurement of magnesium | 107 | $820 |
| Phosphorus inorganic (phosphate) | 107 | $575 |
| Measurement of direct bilirubin | 37 | $210 |
| 2024 | 945 | 6 | 26 | $75,586 |
| 2023 | 1,261 | 8 | 22 | $58,042 |
| 2022 | 546 | 9 | 23 | $32,872 |
| 2021 | 71 | 3 | 14 | $3,874 |
| 2020 | 226 | 2 | 26 | $23,204 |
| 2019 | 521 | 4 | 28 | $59,027 |
| 2018 | 693 | 12 | 28 | $36,063 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 261 | $41,683 |
| Service | 197 | $6,701 |
| Return visit (30+ min) | 42 | $4,473 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 237 | $2,079 |
| Measurement of magnesium | 160 | $1,217 |
| Phosphorus inorganic (phosphate) | 160 | $836 |
| Measurement of direct bilirubin | 134 | $744 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 70 | $309 |
2022
| Long return visit (40+ min) | 135 | $22,103 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 43 | $3,482 |
| Service | 88 | $3,001 |
| Return visit (30+ min) | 19 | $2,131 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 124 | $1,102 |
| COMPREHENSIVE METABOLIC PANEL | 34 | $407 |
| Measurement of magnesium | 41 | $312 |
| Phosphorus inorganic (phosphate) | 41 | $221 |
| Measurement of direct bilirubin | 21 | $114 |
2021
| Return visit (30+ min) | 28 | $3,151 |
| Service | 13 | $443 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 30 | $280 |
2020
| Return visit (30+ min) | 212 | $21,487 |
| Long return visit (40+ min) | 14 | $1,718 |
2019
| Long return visit (40+ min) | 272 | $35,910 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 188 | $15,439 |
| Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture | 26 | $4,078 |
| Return visit (30+ min) | 35 | $3,600 |
2018
| Long return visit (40+ min) | 176 | $21,540 |
| Return visit (30+ min) | 65 | $5,037 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 69 | $4,814 |
| Service | 72 | $2,447 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 100 | $880 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 71 | $416 |
| Vincristine sulfate, 1 mg | 20 | $239 |
| Measurement of direct bilirubin | 35 | $199 |
| Transferase; alanine amino (ALT) (SGPT) | 21 | $126 |
| Measurement of total bilirubin | 22 | $125 |
| Transferase; aspartate amino (AST) (SGOT) | 21 | $123 |
| Creatinine; blood | 21 | $118 |
Money from drug and device companies
$98 in 2025
| 2025 | 1 | 1 | None | $98 |
| 2019 | 1 | 3 | None | $683 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kymriah | $98 | 1 payment
|
See the published payment
| Novartis Pharmaceuticals | Meals · 2025-12-07 | Kymriah | $98 |
See earlier years (2019)
2019: $683
| Genentech | Venclexta | $683 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · Total Therapy Study Xvii (Totxvii) for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphom · 2022 | Their institution | $2,371,908 |
| Amgen Inc. · Total Therapy Study Xvii (Totxvii) for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphom · 2021 | Their institution | $662,130 |
| Amgen Inc. · [Poetic] Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias · 2023 | Their institution | $434,946 |
| Genentech, Inc. · Imatrix Idasa · 2024 | Their institution | $328,497 |
| AbbVie, Inc. · Venclexta · 2019 | Their institution | $224,434 |
| AbbVie Inc. · Venclexta · 2020 | Their institution | $204,286 |
| ABBVIE INC. · A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed;Refractory Acute Lymphoblastic Leukemia Or Relapsed;Refractory Lymphoblastic Lymphoma · 2023 | Their institution | $148,119 |
| Amgen Inc. · [Poetic] Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias · 2024 | Their institution | $135,976 |
| Amgen Inc. · Total Therapy Study Xvii (Totxvii) for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphom · 2020 | Their institution | $132,250 |
| ABBVIE INC. · A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia Or Relapsed/Refractory Lymphoblastic Lymphoma · 2021 | Their institution | $70,496 |
| Genentech, Inc. · Imatrix Idasa · 2022 | Their institution | $69,666 |
| Genentech, Inc. · Imatrix Idasa · 2023 | Their institution | $63,017 |
| Amgen Inc. · [Poetic] Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias · 2021 | Their institution | $38,966 |
| Genentech, Inc. · Imatrix Idasa · 2025 | Their institution | $38,475 |
| Genentech, Inc. · Imatrix Idasa · 2020 | Their institution | $21,830 |
| Syndax Pharmaceuticals, Inc. · Expanded Access Program Forsndx-5613in Patients With Relapsed/Refractory Acute Leukemias With Genetic Alterations Associated With Hoxa Overexpression · 2025 | Their institution | $12,486 |
| Genentech, Inc. · Imatrix Idasa · 2021 | Their institution | $2,048 |
| Amgen Inc. · Total Therapy Study Xvii (Totxvii) for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphom · 2023 | Their institution | $1,580 |
| Amgen Inc. · P1b Monotherapy in Pediatric Patients · 2019 | Their institution | $503 |
| AbbVie, Inc. · Venclexta · 2019 | This clinician | $61 |
Professional record
- NPI
- 1770648586
- Licence
- CA G71335California G71335: Current · expires 2027-01-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 750 Welch Rd Ste 200, Palo Alto, CA, 94304
- NPI first listed
- 2006-12-22
- NPI last updated
- 2024-04-16
- NPI record certified
- 2023-07-07
This is when the NPI record was last certified, not a medical board exam.